[go: up one dir, main page]

DK1222929T3 - Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom - Google Patents

Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom

Info

Publication number
DK1222929T3
DK1222929T3 DK02447005.6T DK02447005T DK1222929T3 DK 1222929 T3 DK1222929 T3 DK 1222929T3 DK 02447005 T DK02447005 T DK 02447005T DK 1222929 T3 DK1222929 T3 DK 1222929T3
Authority
DK
Denmark
Prior art keywords
systemic inflammatory
prevention
treatment
pharmaceutical composition
inflammatory reaction
Prior art date
Application number
DK02447005.6T
Other languages
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Sciences Res Partners Vzw filed Critical Life Sciences Res Partners Vzw
Application granted granted Critical
Publication of DK1222929T3 publication Critical patent/DK1222929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02447005.6T 2001-01-11 2002-01-11 Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom DK1222929T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26140501P 2001-01-11 2001-01-11

Publications (1)

Publication Number Publication Date
DK1222929T3 true DK1222929T3 (da) 2010-09-06

Family

ID=22993164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02447005.6T DK1222929T3 (da) 2001-01-11 2002-01-11 Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom

Country Status (7)

Country Link
EP (1) EP1222929B8 (da)
AT (1) ATE468136T1 (da)
CY (1) CY1110781T1 (da)
DE (1) DE60236386D1 (da)
DK (1) DK1222929T3 (da)
ES (1) ES2346189T3 (da)
PT (1) PT1222929E (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
EP1598368A4 (en) * 2003-01-20 2007-07-25 Chugai Pharmaceutical Co Ltd ANTI-PCI neutralizing ANTIBODY
EP1706079B1 (en) 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
PL1830924T3 (pl) 2004-12-23 2013-08-30 Csl Behring Gmbh Zapobieganie tworzeniu i/lub stabilizacji skrzepu
CA2616902A1 (en) 2005-07-29 2007-02-15 Life Sciences Research Partners Vzw Human inhibitory anti-factor viii antibodies binding to the a2 domain
CN102234641A (zh) * 2010-05-05 2011-11-09 杭州星博生物科技有限公司 一种快速获取特异性人源抗体可变区基因序列的方法
DE102013005184A1 (de) * 2013-03-20 2014-09-25 fzmb GmbH, Forschungszentrum für Medizintechnik und Biotechnologie Verfahren zur Funktionalisierung einer Oberfläche

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
DE60033814T2 (de) 1999-07-14 2007-11-08 D. Collen Research Foundation Vzw Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers

Also Published As

Publication number Publication date
ES2346189T3 (es) 2010-10-13
CY1110781T1 (el) 2015-06-10
EP1222929A2 (en) 2002-07-17
EP1222929B8 (en) 2010-07-07
DE60236386D1 (de) 2010-07-01
ATE468136T1 (de) 2010-06-15
PT1222929E (pt) 2010-08-18
EP1222929B1 (en) 2010-05-19
EP1222929A3 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
CY1110781T1 (el) Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
WO2002042272A8 (en) Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
NO20031471L (no) Glykoformer av faktor VII
NO20031500L (no) Brodekkepaneler, fremgangsmåte for fremstilling av samme og broer omfattende samme
ATE339425T1 (de) Platelet adp rezeptor inhibitoren
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60226154D1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
DK3178934T3 (da) Anti-il-12-antistoffer, sammensætninger, fremgangsmåder og anvendelser til behandling af crohn's patologi
ATE309999T1 (de) Blutplättchen-adp-rezeptor-inhibitoren
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
WO2003048207A3 (en) Anti-dota antibody
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
DK1362052T3 (da) Inhibitorer af cruzipain og andre cysteinproteaser
BRPI0411116A (pt) compostos fundidos que inibem receptor vanilóide de subtipo 1 - receptor (vr1)
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
NO934218L (no) Inhibitorer av cathepsin g og elastase for forhindring av bindevevsned-brytning
EA200400410A1 (ru) Комбинация нспвлс и ингибитора pde-4
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
ATE332145T1 (de) Arzneien zur begleitenden behandlung von glaukomen
ATE553415T1 (de) Lichtempfindliche polyimid-precursor- zusammensetzungen
NL1019899A1 (nl) Verwijdering van onzuiverheden uit koolwaterstofstromen.
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen